Patients with a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies are not eligible
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies
Have a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
Intolerance to or prior severe (?Grade 3) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab).
Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to bakerâ€™s yeast, unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization
History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of anaphylactic reaction to a recombinant protein or hypersensitivity to PEG
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
History of anaphylactic reaction to monoclonal antibody therapy
Patients with intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the study drug (including excipients)
History of anaphylactic reaction to monoclonal antibody therapy
History of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxel
History of anaphylactic reaction to human, or humanized, antibody
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Patients with intolerance to or who have had a severe (>= grade 3) allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the investigational product (including excipients)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of anaphylactic reaction to human, or humanized, antibody
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
History of grade IV anaphylactic reaction to monoclonal antibody therapy
History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibodies (e.g., Enbrel which is the Fc portion of an antibody or Lucentis which is a Fab)
Participants with a history of allergic reactions attributed to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of anti-drug antibodies, severe allergic, anaphylactic, or other infusion-related reaction to a previous biologic agent
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of solid organ transplantation and of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibodies
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to any of the other study drugs
Previous life-threatening anaphylactic reactions to prior monoclonal antibody-based immunotherapy or any component of the moxetumomab pasudotox formulation
Intolerance to rituximab or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugs
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
Transformation of CLL to aggressive B-cell malignancy History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (e.g., patients in whom dosing with obinutuzumab would be contraindicated for safety reasons)
History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
Severe hypersensitivity reaction to apixaban, dalteparin, heparin or pork products (e.g., anaphylactic reactions)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product
History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
History of anaphylactic reactions or severe allergies
Patients with a history of anaphylactic reactions to OTL38
History of anaphylactic reaction to human, or humanized, antibody
Previous anaphylactic reaction to either FDHT or FDG
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to the chemotherapy drugs used in this study, unless the antibody can be given through a desensitization program in consultation with an allergist
Previous anaphylactic reaction to human, humanized or chimeric antibody
Previous anaphylactic reaction to huJ591 antibody or FDG imaging
Participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in TAK-164 formulation.
History of anaphylactic reactions or severe allergies
